Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization

Launched by BENI-SUEF UNIVERSITY · Jul 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of preparing women for in-vitro fertilization (IVF), specifically for those who are expected to have a strong response in producing eggs. The two methods being compared are the Progesterone Primed Ovarian Stimulation (PPOS) protocol, which uses a hormone called Dydrogesterone, and the GnRH Antagonist protocol. The goal is to see which method is more effective and safer for women undergoing a specific type of IVF called ICSI, where eggs are directly injected with sperm.

To participate in this trial, women need to be between certain ages and meet specific health criteria, including having a body mass index (BMI) of 30 or less and certain hormone levels that indicate a good egg reserve. However, women with severe endometriosis, certain uterine issues, or other serious health conditions cannot join. If you qualify and decide to participate, you can expect close monitoring throughout the process to ensure safety and effectiveness. It’s important to know that this trial is not yet recruiting participants, but it aims to provide valuable insights for future IVF treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. undergoing trial of ICSI.
• • 2. BMI ≤ 30
• • 3. AMH ≥3.5
• • 4. AFC ≥ 20
• Exclusion Criteria:
• • 1. Any known contraindications to the approved fertility drugs.
• • 2. Severe endometriosis.
• • 3. Uterine malformations or abnormal uterine cavity.
• • 4. Uncontrolled endocrinopathies:DM,hyperthyroidism, hypothyroidism
• • 5. Severe male factor
• • 6. History of recurrent ICSI failure or recurrent miscarriage